Unknown

Dataset Information

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.


ABSTRACT:

Objective

To assess the role of dutasteride in preventing clinical progression of benign prostatic hyperplasia in asymptomatic men with larger prostates.

Design

Post hoc analysis of four year, double blind Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study

Participants

1617 men randomised to dutasteride or placebo with a prostate size >40 mL and baseline International Prostate Symptom Score (IPSS) <8. Subjects who took medications for benign prostatic hyperplasia were excluded at study entry.

Interventions

Placebo or dutasteride 0.5 mg daily.

Main outcome measures

Comparison of risk of clinical progression of benign prostatic hyperplasia at four years (defined as a ≥ 4 point worsening on IPSS, acute urinary retention, urinary tract infecti

SUBMITTER: Toren P 

PROVIDER: S-EPMC3626257 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature